Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum has reiterated a Buy rating on Recursion Pharmaceuticals (NASDAQ: RXRX) and has maintained a price target of $8 for the stock.